Researcher Dr. Laura Sly
Institution University of
Project Dr. Sly is studying macrophages, a type of cell found
British Columbia in blood, that are often thought of as “bacteria killers”. (Year 1 of 3) This fight often results in inflammation, which helps to stop and destroy the invaders. However, if not properly controlled, it can lead to chronic inflammation like that seen IBD. Dr. Sly is looking at how we might use regulatory macrophages to block inflammation at its source and treat or prevent IBD.
Keywords: regulatory macrophages; animal model; intestinal inflammation; immunotherapy
Dr. Theodore Steiner
University of Dr. Steiner is developing a better approach to British Columbia dampen unwanted inflammation by using the body’s
own tools – namely, white blood cells called T-regulatory cells (Tregs). Treg therapy (taking Tregs from patients’ blood, stimulating them to multiply, and then infusing them back into the bloodstream) can help control inflammation in other diseases, but this has not yet been successful in IBD. In this project, Dr. Steiner will address the current barriers to Treg therapy in two different mouse models. If successful, Treg therapy for IBD patients may become a reality.
Co-Investigator(s): Dr. Megan Levings University of
Dr. Bruce Vallance BC Children’s Hospital
Keywords: T British Columbia inflammasome; cell therapy
-regulatory cells; flagellin; .
Dr. Vallance is investigating the immune signals and cell types involved in protecting intestinal tissues in
order to better understand how the immune system normally balances inflammation with tissue protection. Ultimately, these studies will help to develop new therapies that will balance the immune response in people with Crohn’s and colitis.
Keywords: intestinal epithelial cells; mucosal integrity; innate immunity; enteric bacteria; tissue protection.
Dr. John Wallace University of Calgary
Dr. Wallace is studying how inflammation is turned off and how the processes might be malfunctioning
in IBD. By finding the defect in inflammation regulation, this may lead to better drugs with fewer side effects that will promote healing and reduce symptoms in IBD. Such drugs may also prolong remission and allow patients to stop taking any medications. Dr. Wallace will be testing these experimental drugs in different types of intestinal inflammation to find the best doses and the best routes of administering the drugs.
Co-Investigator(s): Dr. Jose G.P.
University Ferraz of Calgary Keywords: anti-inflammatory mediators;
pro-resolution mediators; translational research; therapeutic targets.
$119,445 (Year 3 of 3) $125,000 (Year 1 of 3) $122,107 (Year 1 of 3)
17 | RESEARCH REPORT 2014
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32